Literature DB >> 32569927

Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.

Hyun Don Yun1, Marie Lue Antony2, Michael A Linden3, Klara E Noble-Orcutt2, Craig E Eckfeldt4, Celalettin Ustun5, Andrew C Nelson3, Zohar Sachs6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32569927      PMCID： PMC7685094          DOI： 10.1016/j.leukres.2020.106404

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  15 in total

1.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Authors:  M Jawhar; J Schwaab; S Schnittger; M Meggendorfer; M Pfirrmann; K Sotlar; H-P Horny; G Metzgeroth; S Kluger; N Naumann; C Haferlach; T Haferlach; P Valent; W-K Hofmann; A Fabarius; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

2.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Authors:  Jason Gotlib; Hanneke C Kluin-Nelemans; Tracy I George; Cem Akin; Karl Sotlar; Olivier Hermine; Farrukh T Awan; Elizabeth Hexner; Michael J Mauro; David W Sternberg; Matthieu Villeneuve; Alice Huntsman Labed; Eric J Stanek; Karin Hartmann; Hans-Peter Horny; Peter Valent; Andreas Reiter
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

3.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 4.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

5.  The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

Authors:  Yingzi Wang; Andrei V Krivtsov; Amit U Sinha; Trista E North; Wolfram Goessling; Zhaohui Feng; Leonard I Zon; Scott A Armstrong
Journal:  Science       Date:  2010-03-26       Impact factor: 47.728

6.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

7.  Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS).

Authors:  Christina Economopoulou; Vassiliki Pappa; Sotiris Papageorgiou; Frieda Kontsioti; Panagiota Economopoulou; Efstratia Charitidou; Kostas Girkas; Violetta Kapsimali; Chrissoula Papasteriadi; Panagiotis Tsirigotis; Efstathios Papageorgiou; John Dervenoulas; Theofanis Economopoulos
Journal:  Ann Hematol       Date:  2009-10-08       Impact factor: 3.673

8.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

9.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

10.  Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.

Authors:  D A C Fisher; O Malkova; E K Engle; C A Miner; M C Fulbright; G K Behbehani; T B Collins; S Bandyopadhyay; A Zhou; G P Nolan; S T Oh
Journal:  Leukemia       Date:  2016-12-23       Impact factor: 11.528
View more
  1 in total

Review 1.  Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.

Authors:  Boguslaw Nedoszytko; Michel Arock; Jonathan J Lyons; Guillaume Bachelot; Lawrence B Schwartz; Andreas Reiter; Mohamad Jawhar; Juliana Schwaab; Magdalena Lange; Georg Greiner; Gregor Hoermann; Marek Niedoszytko; Dean D Metcalfe; Peter Valent
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.